Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Schizochytrium oil is a rich, vegetarian source of the omega-3 fatty acid docosahexaenoic acid (DHA). Its use in supporting or treating metabolic syndrome is primarily based on the known roles of omega-3 fatty acids in cardiometabolic health. Several preclinical and small clinical studies have investigated the impact of omega-3 supplementation, including DHA-rich oils like those derived from Schizochytrium, on markers relevant to metabolic syndrome such as triglycerides, cholesterol, insulin sensitivity, and inflammation.

However, the bulk of the evidence supporting omega-3 use in metabolic syndrome comes from studies using fish oil (which contains both EPA and DHA), not specifically Schizochytrium oil. A few human studies have demonstrated that DHA from Schizochytrium oil can lower triglyceride levels and may modestly improve some aspects of lipid profile. There is limited direct evidence for its effects on insulin resistance, blood pressure, or waist circumference, which are key components of metabolic syndrome.

Overall, while the biological plausibility is high and some early evidence exists, the direct scientific validation for Schizochytrium oil specifically in treating or preventing metabolic syndrome is limited, and larger, high-quality clinical trials are needed. Therefore, its use is supported by scientific rationale but only modest direct evidence.

More about Schizochytrium Oil
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Schizochytrium Oil

Products containing Schizochytrium Oil